We are live on ! Find out more
URGN icon

UroGen Pharma
URGN

172 hedge funds and large institutions have $835M invested in UroGen Pharma in 2026 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 52 increasing their positions, 47 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

32% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 25

11% more call options, than puts

Call options by funds: $4.26M | Put options by funds: $3.83M

11% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 47

3% more funds holding

Funds holding: 167 → 172 (+5)

1.97% more ownership

Funds ownership: 93.38% → 95.36% (+2%)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

18% less capital invested

Capital invested by funds: $1.02B → $835M (-$189M)

Holders
172
Holders Change
+5
Holders Change %
+2.99%
% of All Funds
2.12%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
33
Increased
52
Reduced
47
Closed
25
Calls
$4.26M
Puts
$3.83M
Net Calls
+$423K
Net Calls Change
-$26.3M

Top Buyers

Rank Fund Capital Flow
1
Toronto Dominion Bank
Toronto Dominion Bank
Ontario, Canada
+$52.5M
2
KCM
Kynam Capital Management
New Jersey
+$45.1M
3
OM
Opaleye Management
Massachusetts
+$23.3M
4
SCM
Soleus Capital Management
Connecticut
+$11.6M
5
FCM
Frontier Capital Management
Massachusetts
+$10.7M

Top Sellers

Rank Fund Capital Flow
1
PBA
Paradigm Biocapital Advisors
New York
-$55.5M
2
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
-$14.8M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$11.8M
4
Citadel Advisors
Citadel Advisors
Florida
-$9.42M
5
SCM
Superstring Capital Management
New York
-$6.64M
Name Holding Trade Value Shares
Change 		Change in
Stake
LFG
151
Larson Financial Group
Missouri
$4.39K +$2.08K +104 +74%
CAM
152
Costello Asset Management
Pennsylvania
$3.6K – – –
Optiver Holding
153
Optiver Holding
Netherlands
$2.73K -$1.42K -71 -32%
TPWA
154
Twin Peaks Wealth Advisors
California
$2.16K +$2.41K +120 New
EP
155
Essential Partners
California
$2.12K – – –
Rockefeller Capital Management
156
Rockefeller Capital Management
New York
$2.01K – – –
NA
157
NewEdge Advisors
Louisiana
$1.8K – – –
SAM
158
Smartleaf Asset Management
Massachusetts
$1.22K – – –
RIL
159
Rothschild Investment LLC
Illinois
$1.15K +$281 +14 +28%
PNC Financial Services Group
160
PNC Financial Services Group
Pennsylvania
$1.13K – – –
PFBT
161
Parkside Financial Bank & Trust
Missouri
$810 – – –
AF
162
Allworth Financial
California
$810 +$200 +10 +29%
IA
163
IFP Advisors
Florida
$557 – – –
RFP
164
Root Financial Partners
California
$539 +$601 +30 New
FFA
165
Farther Finance Advisors
California
$455 -$4.65K -232 -91%
DF
166
DecisionPoint Financial
Arizona
$396 – – –
SS
167
SBI Securities
Japan
$360 +$40 +2 +11%
TWD
168
True Wealth Design
Ohio
$288 – – –
S
169
SignatureFD
Georgia
$180 – – –
HFS
170
Hughes Financial Services
Virginia
$54 +$60 +3 New
JWM
171
JPL Wealth Management
Colorado
$18 +$20 +1 New
Renaissance Technologies
172
Renaissance Technologies
New York
– -$5.72M -244,300 Closed
EI
173
EAM Investors
California
– -$3.76M -160,412 Closed
TD Asset Management
174
TD Asset Management
Ontario, Canada
– -$1.88M -80,188 Closed
NIM
175
NEOS Investment Management
Connecticut
– -$1.25M -53,576 Closed
4 5 6
7
8

URGN Hedge Fund Activity: Q1 2026 in Review

172 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q1 2026, worth a combined $835M — down 18% from $1.02B a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new URGN positions and 25 closed out — a net gain of 8 holders — while 52 added to existing stakes and 47 trimmed.

The largest buyer was Toronto Dominion Bank, opening a new position worth an estimated $52.5M. The largest seller was Paradigm Biocapital Advisors, cutting an estimated $55.5M.

  • 172 institutional investors held UroGen Pharma (URGN) as of Q1 2026, up from 167 in Q4 2025.
  • Funds reported $835M of UroGen Pharma stock for Q1 2026, down 18% quarter-over-quarter.
  • 33 funds opened new UroGen Pharma positions in Q1 2026 and 25 closed out, a net change of +8 holders.
  • The largest UroGen Pharma buyer in Q1 2026 was Toronto Dominion Bank, an estimated $52.5M added.
  • The largest UroGen Pharma seller in Q1 2026 was Paradigm Biocapital Advisors, an estimated $55.5M sold.

Based on aggregated 13F filings for Q1 2026.